Follow us on Bluesky
Bluesky · Hashtag

#ESCCongress

283
posts · 30d
45
users
9
posts / day
6.3
posts / user
-69% vs last week

#ESCCongress is an active hashtag on Bluesky. In the last 30 days, 45 people shared 283 posts with it — around 9 a day. Activity is down 69% versus the previous week, peaking on Aug 28 with 75 posts.

#ESCCongress posts per day (last 30 days)

Related tags

Tags most often used together with #ESCCongress.

#CardioSky 73 #Kardiologie 20 #HeartFailure 18 #ESC2026 15 #AI 14 #AorticStenosis 13 #ESCCongress2026 12 #PCI 11 #Cardiology 8 #AtrialFibrillation 7 #Echocardiography 6 #AFib 5

Posts with #ESCCongress

JAMA
@jama.com
about 1 year ago
Editorial: Recent advancements and clinical trials emphasize the importance of recognizing #RSV as a health threat in older adults, with vaccines offering protection against severe disease and potentially broader cardiopulmonary benefits. #ESCCongress #WCCardio ja.ma/4n4umz8
A JAMA editorial from August 30, 2025, titled: "Shot Through the Heart—Can RSV Vaccination Reduce Risk of Cardiovascular Outcomes?" by Helen Y. Chu, MD, MPH; Alastair F. Murray, MD. The article discusses RSV's impact on older adults with heart conditions.
0 9 22
NEJM.org
@nejm.org
about 1 year ago
Late breaking: In pts with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite device-related complications. Full DanGer Shock trial results: nej.md/47JkdDE #ESCCongress
Time-to-event curves for death from any cause during 10 years of follow-up
0 3 18
NEJM.org
@nejm.org
27 days ago
In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: nej.md/4ii61XB #ESCCongress
A graph from the Original Article "Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk." The trial name, SINGLE-AF, is in parentheses after the title. The graph shows the cumulative incidence of primary end-point events (intention-to-treat population). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.
0 9 15
JAMA
@jama.com
about 1 year ago
Editorial: Recent advancements and clinical trials emphasize the importance of recognizing #RSV as a health threat in older adults, with vaccines offering protection against severe disease and potentially broader cardiopulmonary benefits. #ESCCongress #WCCardio ja.ma/4n5Ryx0
A JAMA article titled "Shot Through the Heart—Can RSV Vaccination Reduce Risk of Cardiovascular Outcomes?" by Helen Y. Chu, MD, MPH; Alastair F. Murray, MD. Published online August 30, 2025.
0 3 15
JAMA
@jama.com
about 1 year ago
In adults aged 60 years or older, RSV vaccines reduced RSV-associated hospitalizations over 2 seasons, although effectiveness waned among immunocompromised patients and those with cardiovascular disease. #ESCCongress #WCCardio ja.ma/47puFQR
Two bar graphs titled "Respiratory Syncytial Virus (RSV)-Associated Hospitalizations and Vaccinations" and "No. of Hospitalized Adults with RSV Vaccination" showing monthly data from 2023-2025. The first graph shows hospitalizations, and the second, RSV vaccinations.
0 2 13
NEJM.org
@nejm.org
27 days ago
Among adults with endocarditis caused by 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴, 𝘌. 𝘧𝘢𝘦𝘤𝘢𝘭𝘪𝘴, or streptococcus species, tailored-duration antibiotic therapy led to 13 more days alive without antibiotics than standard therapy, but with a higher incidence of relapse. POET II trial results: nej.md/3UGyah8 #ESCCongress
Two panels showing the primary efficacy and safety end points. Panel A is a bar graph that shows the median number of days alive without antibiotic therapy for infective endocarditis or bacteremia within 6 months after randomization (the primary efficacy end point) among patients in the tailored-therapy and standard-therapy groups. Panel B shows the Kaplan–Meier estimates of the probability of a composite of death from any cause, unplanned cardiac surgery, or symptomatic embolic events within 6 months after randomization (the primary safety end point).
1 7 12
European Society of Cardiology
@escardio.bsky.social
about 1 year ago
✨ #ESCCongress in Madrid = good vibes, big smiles & science that connects us all! 💙 From networking moments 🤝 to packed sessions and plenty of laughter 😄 the energy is just unbeatable. Here’s a look at how we kicked things off 🎉 👉 Swipe through to relive the highlights! #cardiology #ESC75years
0 3 12

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

View all posts on Bluesky

Explore trending tags

#art #oc #nsfw #furry #digitalart #fanart #furryart #AI #photography #gay #illustration #fcf
Back to all tags